132 related articles for article (PubMed ID: 34244341)
81. [Neuroendocrine carcinoma of breast: a study of tumor morphology and subtyping].
Gao LX; Liu G; Li L; Lin HY; Jin H; Cheng J; Jin ML; Ding HY
Zhonghua Bing Li Xue Za Zhi; 2011 Sep; 40(9):604-9. PubMed ID: 22177244
[TBL] [Abstract][Full Text] [Related]
82. Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma.
Ayadi L; Khabir A; Amouri H; Karray S; Dammak A; Guermazi M; Boudawara T
World J Surg Oncol; 2008 Oct; 6():112. PubMed ID: 18945339
[TBL] [Abstract][Full Text] [Related]
83. Estrogen receptor and progesterone receptor status in breast cancer in relation to age, histological grade, size of lesion and lymph node involvement.
Sofi GN; Sofi JN; Nadeem R; Shiekh RY; Khan FA; Sofi AA; Bhat HA; Bhat RA
Asian Pac J Cancer Prev; 2012; 13(10):5047-52. PubMed ID: 23244108
[TBL] [Abstract][Full Text] [Related]
84. Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan.
Almasri NM; Al Hamad M
Breast Cancer Res; 2005; 7(5):R598-604. PubMed ID: 16168103
[TBL] [Abstract][Full Text] [Related]
85. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
[TBL] [Abstract][Full Text] [Related]
86. Differential amplification and overexpression of HER-2/neu, p53, MIB1, and estrogen receptor/progesterone receptor among medullary carcinoma, atypical medullary carcinoma, and high-grade invasive ductal carcinoma of breast.
Xu R; Feiner H; Li P; Yee H; Inghirami G; Delgado Y; Perle MA
Arch Pathol Lab Med; 2003 Nov; 127(11):1458-64. PubMed ID: 14567723
[TBL] [Abstract][Full Text] [Related]
87. Estrogen receptor, progesterone receptor, HER2/neu, P53 and Ki-67 status of male breast carcinomas in Pakistan.
Jamal S; Mushtaq H; Mubarik A; Malik TM
Asian Pac J Cancer Prev; 2009; 10(6):1067-70. PubMed ID: 20192585
[TBL] [Abstract][Full Text] [Related]
88. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
[TBL] [Abstract][Full Text] [Related]
89. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
[TBL] [Abstract][Full Text] [Related]
90. Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing?
Bethune GC; Pettit AS; Veldhuijzen van Zanten D; Barnes PJ
Histopathology; 2017 May; 70(6):966-974. PubMed ID: 28032917
[TBL] [Abstract][Full Text] [Related]
91. Discordance Rate in Estrogen Receptor, Progesterone Receptor, HER2 Status, and Ki67 Index Between Primary Unifocal and Multiple Homogenous Breast Carcinomas and Synchronous Axillary Lymph Node Metastases Have an Impact on Therapeutic Decision.
Georgescu R; Boros M; Moncea D; Bauer O; Coros MF; Oprea A; Moldovan C; Podoleanu C; Stolnicu S
Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):533-538. PubMed ID: 28099174
[TBL] [Abstract][Full Text] [Related]
92. Joint detection of multiple immunohistochemical indices and clinical significance in breast cancer.
Qiao EQ; Ji M; Wu J; Li J; Xu X; Ma R; Zhang X; He Y; Zha Q; Song X; Zhu L; Tang JH
Mol Clin Oncol; 2013 Jul; 1(4):703-710. PubMed ID: 24649232
[TBL] [Abstract][Full Text] [Related]
93. Assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status in the fine needle aspirates of metastatic breast carcinomas.
Monaco SE; Wu Y; Teot LA; Cai G
Diagn Cytopathol; 2013 Apr; 41(4):308-15. PubMed ID: 22045649
[TBL] [Abstract][Full Text] [Related]
94. Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast.
Baqai T; Shousha S
Histopathology; 2003 May; 42(5):440-7. PubMed ID: 12713620
[TBL] [Abstract][Full Text] [Related]
95. WT1 immunoreactivity in breast carcinoma: selective expression in pure and mixed mucinous subtypes.
Domfeh AB; Carley AL; Striebel JM; Karabakhtsian RG; Florea AV; McManus K; Beriwal S; Bhargava R
Mod Pathol; 2008 Oct; 21(10):1217-23. PubMed ID: 18469795
[TBL] [Abstract][Full Text] [Related]
96. Breast Carcinoma - A Comparative Study of Immunohistochemistry and Fluorescence in Situ Hybridization for Her-2 Assessment and Association of ER, PR, HER-2 and Ki-67 Expression with Clinico-Pathological Parameters.
K S; Arumugam M; Shetty J; Shetty RA; Asani R; Shetty PD
Iran J Pathol; 2022; 17(4):435-442. PubMed ID: 36532645
[TBL] [Abstract][Full Text] [Related]
97. Clinicopathological pattern of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 over-expression of epithelial ovarian carcinomas in Nigeria.
Ajani MA; Lawan A; Oke T; Khramtsova G; Nwanji I; Salami A; Awolude O; Ebili H; Onwukamuche ME; Sveen E; Yoshimatsu T; Olopade OI
Afr Health Sci; 2023 Sep; 23(3):236-244. PubMed ID: 38357171
[TBL] [Abstract][Full Text] [Related]
98. Clinicopathological features and genomic profiles of a group of secretory breast carcinomas in which progressive cases have more complex genomic features.
Lei T; Yang Y; Shi Y; Deng X; Peng Y; Wang H; Chen T
Diagn Pathol; 2022 Dec; 17(1):101. PubMed ID: 36585729
[TBL] [Abstract][Full Text] [Related]
99. Tumour budding in invasive breast carcinoma and its correlation with histopathological prognostic parameters and hormone receptor status.
Kundu T; Giri R; Hota SK; Sahu SK; Senapati U
J Cancer Res Ther; 2023 Jan; 19(Suppl 2):S664-S668. PubMed ID: 38384036
[TBL] [Abstract][Full Text] [Related]
100. Clinical/prognostic significance of Syndecan-1 expression in invasive breast carcinoma with distant metastasis and its correlation with tumor immunity.
Wang H; Zhang Y; Yang Z; Jiang Y; Wu L; Wang R; Zhang Z
Pathol Res Pract; 2023 Oct; 250():154787. PubMed ID: 37678063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
